Diagnosis and Staging of Triple Negative Breast Cancer (TNBC)

  • Diagnosis:
    • Triple-negative means cancers that have less than 1 percent expression of ER and PR as determined by immunohistochemistry (IHC), and that are either 0 to 1+ by IHC, or IHC 2+ and fluorescence in situ hybridization (FISH)-negative (not amplified):
      • According to American Society of Clinical Oncology / College of American Pathologists (ASCO/CAP) guidelines
  • Receptor testing and the cut-offs used to determine ER, PR, and HER2 statuses:
    • Were developed to determine the odds of response to endocrine and HER2-directed therapy, respectively:
      • They were not developed to distinguish a distinct biologic subtype of breast cancer:
        • Such as the “triple-negative” phenotype
  • In support of this definition of ER and PR receptor-negative status:
    • An analysis of cooperative group studies with centrally determined ER, PR, and molecular subtype suggests that this group is molecularly heterogeneous, including both luminal and nonluminal subtypes
  • Staging:
    • The clinical staging of breast cancer is identical across breast cancer subtypes using the American Joint Committee on Cancer and the International Union for Cancer Control (AJCC-UICC) Tumor, Node, Metastasis (TNM) breast cancer staging system
#Arrangoiz #BreastSurgeon #CancerSurgeon #SurgicalOncologist #MountSinaiMedical #MSMC #Miami #Mexico #BreastCancer #TripleNegativeBreastCancer

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s